drugset / Trial / NCT06293690
Toripalimab Combined With SBRT for NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC
Timeline
- Start
- 2024-04-15
- Primary completion
- 2025-12-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |